tiprankstipranks
pc:auspe

AusperBio

3 E 3rd Ave San Mateo, California 94401, US
https://www.ausperbio.com/
AusperBio is a clinical-stage biopharmaceutical company operating in the USA and China, focused on developing transformative oligonucleotide therapies, particularly targeting a functional cure for chronic hepatitis B. Utilizing its proprietary Med-Oligo™ ASO platform, the company enhances antisense oligonucleotide therapeutics, aiming to address a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

Leadership & Board

Current Number of Employees9
Current LinkedIn Followers947

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$186M
Total Amount Raised$186M
Total Funding Rounds3
Total Funding Rounds3
Latest Funding Amount$63M
Latest Funding Amount$63M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

AusperBio had 9 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
9Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

AusperBio had 947 followers as of April 6, 2026. The number of followers increased by 4 (0.42%) week-over-week.
947Latest Followers Count
4(0.42%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 22, 2025
Series B
$63.00M
Aug 14, 2025
Series B
$73.00M
May 28, 2025
Series B
$50.00M

Investors

Investor Name
Funding Round
Series B (2)
Series B (2)
Series B (2)
Series B (2)

Related News and Analysis